BELLINGER ANDREW (Chief Scientific Officer) sold 11.5% of their position (865.00 shares) of VERVE THERAPEUTICS, INC. on the open market
Open‑market sale worth $19.9K — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 12/2/2022ACC: 0001209191-22-059438
Officer· Chief Scientific Officer
Since Jun 2021
-865.00
Net shares
Net seller
$19.9K
Total sold
1
Open market trades
0B · 1S
1
Total transactions
865.00 disposed
Non-Derivative Transactions1
Common Stock
Direct
Shares
−865.00
Price / share
$22.95
Trade value
$19.85K
% of position
11.5%
12/1/2022
7.49K→6.63K
Total
Net shares
−865.00
Net value
-$19.85K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 12/1/2022 | S · Sale | −865.00 | $22.95 | $19.85K | 11.5% | 7.49K | 6.63K |
| Total | −865.00 | -$19.85K | ||||||
Derivative Transactions0
No derivative transactions reported